Indian national Sanjay Kumar, 45, on March 9, was sentenced to 43 months in prison and one year of supervised release for conspiring to sell tens of thousands of dollars’ worth of counterfeit oncology ...

Indian national Sanjay Kumar has been sentenced to nearly four years in prison for carrying out a conspiracy to sell fake ...

A 45-year-old Indian national, Sanjay Kumar, was sentenced Thursday to 43 months in federal prison for his role in a ...

An Indian national has been sentenced for conspiring to sell counterfeit cancer drugs in the US, highlighting the dangers of ...

A federal judge in Houston sentenced a man to 43-months in prison and ordered him to pay restitution after he was convicted ...

A 45-year-old man has been sentenced to prison for his role in selling tens of thousands of dollars' worth of counterfeit ...

Merck presents positive results from phase 3 LITESPARK-022 trial of Keytruda plus Welireg in certain patients with earlier-stage RCC at 2026 ASCO cancers symposium: Rahway, New Je ...

Merck & Co. MRK and Bristol Myers Squibb BMY are major global drugmakers with expansive, diversified portfolios. Merck stands out for its leadership in oncology, complemented by strong positions in ...

The pembrolizumab regimen reduced the risk of disease progression or death by 28% and reduced the risk of death by 24% compared with placebo plus paclitaxel with or without bevacizumab. The Food and ...

For all its success across a wide range of cancer types, Merck’s PD-1 superstar Keytruda has never been able to crack the code for one of the toughest-to-treat indications in oncology—ovarian cancer.